Le Lézard
Classified in: Health, Science and technology, Business
Subject: DIV

Thermo Fisher Scientific Declares Quarterly Dividend


WALTHAM, Mass., May 24, 2018 /PRNewswire/ -- Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced that its Board of Directors has declared a quarterly cash dividend of $0.17 per common share, payable on July 16, 2018, to shareholders of record as of June 15, 2018.

Thermo Fisher Scientific (PRNewsfoto/Thermo Fisher Scientific)

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc. (NYSE: TMO) is the world leader in serving science, with revenues of more than $20 billion and approximately 70,000 employees globally. Our mission is to enable our customers to make the world healthier, cleaner and safer. We help our customers accelerate life sciences research, solve complex analytical challenges, improve patient diagnostics, deliver medicines to market and increase laboratory productivity. Through our premier brands ? Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific and Unity Lab Services ? we offer an unmatched combination of innovative technologies, purchasing convenience and comprehensive support. For more information, please visit www.thermofisher.com.

Media Contact Information:

Ron O'Brien

781-622-1242

[email protected]

www.thermofisher.com

 

or

 

Investor Contact Information:
Ken Apicerno
781-622-1294
[email protected]

SOURCE Thermo Fisher Scientific


These press releases may also interest you

at 09:00
Dental Care Acworth is thrilled to utilize this remarkable innovation and offer patients unbiased, objective and standardized dental care that they know they can trust. The AI solutions Pearl delivers can assist dental...

at 09:00
Tolland Hill Family Dental is thrilled to announce the addition of Dr. Conway Ma to its esteemed team of dental professionals. Tolland Hill Family Dental offers a wide range of services, catering to patients of all ages. From a child's first dental...

at 09:00
Amgen today announced the imminent submission of a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for teprotumumab, a fully human monoclonal antibody and targeted inhibitor of the insulin-like growth factor-1...

at 09:00
Ractigen Therapeutics, a leader in the development of small activating RNA (saRNA) therapeutics, announced today that the U.S. Food and Drug Administration (FDA) has approved the company's Investigational New Drug (IND) application for RAG-01, a...

at 09:00
Arbele, a clinical-stage biotechnology company focused...

at 08:53
Alera Health, a leader in population health management integrating behavioral healthcare, is proud to announce its recognition as one of the Great Employers to Work for in North Carolina by Best Companies Group. The 2024 Great Employers to Work for...



News published on and distributed by: